Decentralized Clinical Trials
How to deliver the complex efficiently

"Owing to the pandemic, almost 53.5% of the clinical trials have been suspended" (Frost & Sullivan PB21-52 August 2020)

Covid19 has had a huge impact on the clinical trials environment. “On 18 March, Addex announced that it would delay the start of a clinical trial to treat involuntary movements in people with Parkinson’s disease. The following week, the pharmaceutical giant Eli Lilly in Indianapolis, Indiana, announced that it would halt enrollment in ongoing studies and delay the launch of new trials.” (Ledford, H 2020). The Covid19 pandemic has clearly highlighted the weaknesses of the traditional site centric clinical trial designs.
"85% of all clinical trials fail to recruit enough patients, 80% are delayed due to recruitment problems and dropout rates are high..." (Biopharmadive.com 2019). With community based clinical trials, not only will patients find participation easier, but sites will see increased and faster recruitment rates and sponsors will be able to recruit patients from wider geographical areas, leading to drugs entering the market quicker and more efficiently.

More than ever, people are talking about direct to patient, decentralized or community based clinical trials, it feels like the most recent buzzword in the industry, but as the organization who pioneered these kinds of studies, 14 years ago, we know that it isn’t an easy process. This isn’t about taking the complex and making it simple, it’s about making the complex happen efficiently and safely.

Ensuring patients are safe, cared for and comfortable during treatment isn’t simple; making sure data is collected on schedule and accurately, so that the study either proves the efficacy of a treatment or disproves it quickly isn’t simple; coordinating medical professionals, patients, investigational medicinal product to a single point in time and location isn’t simple; managing sample collection, on site processing and shipping to central laboratories from multiple, domestic, locations isn’t simple. Pulling this all together across multiple patients, locations and visits is very complex. Our operational teams bring together the best in the industry to coordinate each and every study touchpoint and ensure your clinical trial can be run in the patient’s communities in an efficient and safe manner; but it isn’t simple.

Imagine running a clinical trial from a hospital site; you have three patients to coordinate, you need to liaise with the site pharmacy, ensure samples are collected and processed and data is collected and collated into the system. Now imagine that you are doing that for patients at home. Because they don’t have to come to site your patient population has just expanded, instead of 3 patients you have 10 and you now need to coordinate a nurse and courier for every study appointment
The patient needs to be at a fixed location (home, work, school, etc) the nurse needs to arrive on time and the courier needs to arrive within the correct window to ensure the IMP stays within the stability period required. Not only that but the courier needs to have collected the IMP from a central pharmacy that you have liaised with and deliver the samples back to the central lab within the time period for them to be valid. You need to make sure the nurse has all the equipment and supplies they need, including portable centrifuges or other specialist equipment. And then the data collected needs to be checked before it is sent back to the study team. This sounds like a huge undertaking, but it’s what MRN deliver daily for our customers. With a visit completion rate of >98% we know what we’re talking about when it comes to community based clinical trials.

**What do you need to consider?**

Here are some of the points you should consider if looking to run community based clinical trials:

1. **What does the protocol entail?**
   a. What can be done within the protocol in a home/work/school environment? Which visits should happen outside of the site? Is the protocol very visit intensive – be that frequent visits or intensive assessments? What patient centric recommendations can be made to best fit the recruitment, enrollment and retention for the study? MRNs simple rule for research activity taking place outside of the site is that if it can be done by a nurse, the equipment required can be carried, and the IMP is proven to be safe for home administration, then the visit can take place in the home, place of work or school.

2. **Who are your patients?**
   a. You need to think about your target population; where are they, who are they, what is the prevalence of the disease and how close are those patients likely to be to the sites? “Currently, 70% of potential clinical trial patients live more than two hours from a study center...” (Parexel, 2019)
If you want to have regular interaction between the patient and their physician, then it makes sense to have that patient relatively close to site. If those patients aren’t near to a site, they are going to struggle to meet the visit demands of the protocol and they’ll either not enroll or not be retained for the full duration of the trial.

b. Developing the protocol with the patient in mind is absolutely key. Speak to patient advocacy groups for the disease state, they know what it’s like from the patient perspective to take part in a clinical trial, they know how onerous it can be and understand the difficulties of the disease state that they’re trying to manage.

c. Family often have to take the patients to their visits so that should also be considered. Location is key to reduce the burden on the patient and their caregivers or families. Patients shouldn’t be expected to travel hundreds of miles to see a physician or undertake a trial session at site.

d. If you are looking at using technology to facilitate virtual visits you must consider the age of the patient population. Will they know how to use a heart rate monitor or a tablet?

e. Do you have socio-economic information about the patient population or geographic locations the study will be undertaken in?

To be applying technology to a protocol you need to consider the infrastructure of the countries that you will be working in; how good is the WIFI, the broadband? Will 5G be supported? Do the patients have a WIFI network that can be used?

3. What is the treatment?

a. Safe IMP home administration is something we look at closely. We look at the dosing numbers, the safety data listed in the protocol and we also review the IB or pharmacy manual to fully understand whether that IMP can be administered in the home. It’s also important to consider the visit logistics, particularly if taking blood samples or administering IMP; will the IMP be coming out of a central or local pharmacy? Does pharmacy set up need support? What courier services do you need to utilize, and will they need dry ice? There needs to be a thorough safety review of the treatment by qualified individuals from a nursing, pharmacy, project management, and contracting perspective.
4. Who or what do you need?

a. A lot of detail is required around the actual scope of what needs to be delivered. Nurses conducting visits have a higher success rate if trained properly. What training and equipment is required for the research activities required? What experience do the nursing professionals require to deliver the research assessments? How do you ensure all research nurses are vetted appropriately? What training materials and support must be created to ensure all activities can be undertaken correctly?

5. Are there country specific regulations that need to be considered?

a. There may be country specific regulations that may complicate the running of clinical trials in the community. For instance, in some countries we know the administration of certain drug types is forbidden outside of a clinic or hospital environment, or it may require a physician rather than a nurse to perform either the assessments or the administration. It’s not just the clinical research regulations that you need to familiarize yourself with, you need to broaden your understanding of the healthcare landscape in all countries that are being used for the study.

b. As well as regulatory differences country to country, there are also cultural differences to consider as well. In some countries it isn’t polite for patients to invite professionals other than their physician into their home and that would extend to nurses.

"Currently 70% of potential clinical trial participants live more than two hours from a study center..."
6. **What are the data points to be captured?**

a. For early touchpoints in complex studies we suggest detailed oversight from a nurse manager or local country lead to ensure the nurse can complete all research activities accurately. Do you need to include a quality check on data for the first visits per individual nurse? Do you need to perform gap checking for accuracy on source documentation?

b. While studies are ongoing, we would recommend having independent internal quality check and audit groups checking and monitoring all data on a regular basis. We also suggest using independent auditors to look at all projects and processes. For the best results, you want everyone in the network delivering study visits to work from the same SOPs. For data collection to be consistent it’s imperative that your study is managed centrally by your trial vendor.
For some countries COVID lockdown precautions are changing, but the challenges aren’t going away. We’re seeing the cost of running clinical trials increasing; with current estimates at $2.5 billion to get a drug to market. (DiMasi, J et al 2015) Traditional clinical trials are taking longer with recruitment and retention pressures continuing to exert force and recruitment and retention rates continuing to drop.

In the twentieth annual analysis of emerging clinical trial enrollment benchmarks from Parexel we see the median number of patients per nda dropping from 5,034 in 2015 to 3,452 in 2017 (Parexel 2018). All of this is wrapped around increasing pressures from regulators who are thirsty for more robust data.

Many organizations are looking at telemedicine to support this dip in recruitment and enrolment for trials with “Nearly two-thirds of research sites monitored by WCG Clinical, a company that collects information on 93% of industry-sponsored trials across 3000 global institutions, have adopted telemedicine in some capacity to conduct trials during COVID-19.” (Cahan, E 2020) but we know from experience that telemedicine isn’t a one size fits all for clinical trials. It is effective in improving communication around clinical trials but can’t efficiently manage the complexities of delivering a decentralized trial. The importance of telemedicine in decentralized clinical trials will be covered in our next upcoming whitepaper.

**Conclusion**

Our advice would be to look at each protocol on a case by case basis, understand what your patient population needs and adapt accordingly. For over 14 years community based clinical trials have improved recruitment and retention rates, and with the appropriate safety precautions staying in place around site access they are an ideal way to ensure continued research while still ensuring patient safety and data quality. If you are partnering with an expert in the field, make sure they have global reach, central management, and the ability to deliver locally in the communities you need to include.

The details in decentralized clinical trials are complex, but with the right expertise and systems they can be delivered safely and efficiently providing you and the patients with significant benefits.
The details in decentralized clinical trials are complex, but with the right expertise and systems they can be delivered safely and efficiently providing you and the patients with significant benefits.

Resources


Parexel (April 2018) Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2017, Barnett Parexel Sourcebook 18/19


Tuffts (January/February 2013) Impact Report https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5aa2c28fec212d49f36cc8a/1520616079359/Jan-Feb+2013+IR+summary.pdf [Accessed 20 August 2020]